Navigation Links
Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
Date:9/11/2007

LAUSANNE, Switzerland, September 11 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in oncology and serious medical conditions, today announced that it received current Good Manufacturing Practices (cGMP) certification from Swissmedic for the chemical, physical and biochemical quality control work conducted at its laboratory in Gland, Switzerland. At the same time, certification of the Lausanne site was extended for the manufacture of medicinal products, including the packaging of investigational medicinal products. This achievement gives Debiopharm the alternative to handle its analytical development, formulation and quality control activities in-house when necessary.

"This certification is very important for the optimal development of our products," said Kamel Besseghir, CEO of Debiopharm. "Our laboratory in Gland is the internal quality reference for our outsourced activities in CMC (chemistry, manufacturing and control). We now have more flexibility and reactivity in CMC development, analysis and supply of drug products for clinical studies, one of our major strengths."

Debiopharm also has a cGMP development and production facility in Martigny, Switzerland, which has been inspected by the United States Food and Drug Administration (FDA) and Swissmedic. The company can produce pilot batches of cGMP drug products for feasibility studies, clinical trial supplies and commercial scale manufacturing.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, dr
'/>"/>

SOURCE The Debiopharm Group
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Lucigen receives $750K grant to boost biofuel yields
3. Medical College receives $1.4M cancer grant
4. Wisconsin biotech firm receives $107K NIH grant
5. InvivoSciences receives NIH grant for heart technology
6. Medical College receives $11 million grant to study high blood pressure
7. Madison business receives $115,000 of new state biofuels funding
8. Superior receives funds for technical training
9. UWM receives state funding for plastics research
10. GEs Centricity EHR receives federal certification
11. WHIE receives state eHealth Initiative contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... The California Healthcare Institute ... representing leading California academic institutions, biotechnology, medical device, ... today released a report revealing that California ... The trend shows a 4 percent increase between ... Industry Report indicates that, while biopharmaceutical and ...
(Date:11/21/2014)... 2014 Deep Research Report on Global ... and in-depth research report on the Sodium ferrocyanide ... its definition, classification, application, and industry chain structure ... the international market analysis, including China’s domestic market ... Europe, Asia, China, Japan etc. regions) industry analysis ...
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or ... month periods ended September 30, 2014.  Biorem,s complete 2014 third quarter ... ). Financial Summary:Three-months ended September 30, , ... share data) , 2014 , 2013 ... , 5,281 , 6,715 , ...
(Date:11/18/2014)... Athena Signature Series: Turning Cancer ‘Off’ – featuring Dr. ... in the Regulatory Biology Laboratory at the Salk Institute, studies ... an “off switch” for drug resistance in cancer. , Learn ... is making a global impact in the fight against cancer. ... Cheryl K. Goodman, CEO of Social Global Mobile LLC, for ...
Breaking Biology Technology:California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3
... , COLUMBIA, Md., Sept. 8 Martek Biosciences ... of judges on the United States Court of Appeals for the ... to a patent infringement lawsuit between Martek and Lonza, Ltd., Nutrinova ... The appeals involve Lonza,s U.S. sale and use of DHA ...
... $5 Million Loan Will Leverage $15 Million ... , HARRISBURG, Pa., Sept. 8 Early-stage life ... create quality jobs with the help of a state investment in ... "The life sciences are a growth sector for Pennsylvania," ...
... Inc. (TSX: ONC, NASDAQ: ONCY ), will present ... Renshaw 11th Annual Healthcare Conference on Thursday, September 10, ... at the New York Palace Hotel from September 9 to ... will be available at: http://www.wsw.com/webcast/rrshq15/oncy or on the ...
Cached Biology Technology:Federal Circuit Rules in Martek's Favor in Appeal of Patent Infringement Case 2Federal Circuit Rules in Martek's Favor in Appeal of Patent Infringement Case 3PA Helping Life Science Companies Secure Venture Capital Needed to Expand, Gov. Rendell Says 2Media Advisory - Oncolytics Biotech Inc. to Present at Rodman Renshaw 11th Annual Healthcare Conference 2
(Date:11/4/2014)... the right time might actually help boost a species, ... in understanding animal populations, pest control and managing fish ... journal Trends in Ecology and Evolution , a ... kind of positive population effect an overall species experiences ... the size and developmental stage of the creatures that ...
(Date:11/4/2014)... – (Nov. 4, 2014) – A majority of Madagascar,s ... that could have serious consequences for the rainforests they ... shows the positive impacts lemurs can have on rainforest ... their disappearance could have on the region,s rich biodiversity. ... have fruits eaten by lemurs. Lemurs in turn ...
(Date:11/3/2014)... birth weight and preterm birth are linked to increased ... published in the American College of Rheumatology (ACR) journal, ... birth weight and pre-term babies were not at greater ... , According to the ACR, 27 million Americans ... OA. Symptoms of OA range from mild to severe ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Preterm, low birth-weight babies may need new hips in adulthood 2
... long been considered a major risk factor for cardiovascular ... risk, but the mechanisms of how arteries stave off ... the Perelman School of Medicine, University of Pennsylvania, Wistar ... that the protein apolipoprotein E (apoE) plays a major ...
... the Nowgen Schools Genomics Programme website launches with a range ... genetics in schools and colleges. , Developments in genetics research ... at a cost of $3 billion to sequencing a genome ... genetics in classroom education have remained relatively static. The pace ...
... Research led by Chu Chen, PhD, Associate Professor of Neuroscience ... enzyme called Monoacylglycerol lipase (MAGL) as a new therapeutic target ... online November 1, 2012 in the Online Now section of ... that inactivation of MAGL, best known for its role in ...
Cached Biology News:Softening arteries, protecting the heart 2Softening arteries, protecting the heart 3Bridging the gap between genomics and education 2LSUHSC research identifies new therapeutic target for Alzheimer's disease 2
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
BACE (CT) rabbit polyclonal antibody...
Rabbit polyclonal to MA2 ( Abpromise for all tested applications). entrezGeneID: 10687 SwissProtID: Q9UL42...
Biology Products: